Casi pharmaceuticals receives cta approval from china's nmpa for cid-103 in immune thrombocytopenia

Beijing, china / accesswire / october 24, 2024 / casi pharmaceuticals, inc. (nasdaq:casi), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the center for drug evaluation (cde) of china's national medical products administration (nmpa) has approved the company's clinical trial application (cta) to proceed with a phase 1/2 study of cid-103 in adults patients with chronic immune thrombocytopenia (itp) in china. this china study is part of the global study that was approved by the us fda in may 2024.
CASI Ratings Summary
CASI Quant Ranking